Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd banner

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329

Watchlist Manager
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Logo
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Watchlist
Price: 39.96 CNY 0.18% Market Closed
Market Cap: ¥30.8B

EV/GP

7.4
Current
2%
More Expensive
vs 3-y average of 7.2

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
7.4
=
Enterprise Value
¥27.1B
/
Gross Profit
¥3.6B

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
7.4
=
Enterprise Value
¥27.1B
/
Gross Profit
¥3.6B

Valuation Scenarios

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is trading above its 3-year average

If EV/GP returns to its 3-Year Average (7.2), the stock would be worth ¥39.18 (2% downside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-9%
Maximum Upside
+84%
Average Upside
19%
Scenario EV/GP Value Implied Price Upside/Downside
Current Multiple 7.4 ¥39.96
0%
3-Year Average 7.2 ¥39.18
-2%
5-Year Average 6.7 ¥36.29
-9%
Industry Average 7.6 ¥40.99
+3%
Country Average 13.6 ¥73.67
+84%

Forward EV/GP
Today’s price vs future gross profit

Not enough data available to calculate forward EV/GP

Peer Comparison

All Multiples
EV/GP
P/E
All Countries
Close
Market Cap EV/GP P/E
CN
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
30.8B CNY 7.4 14.4
US
Eli Lilly and Co
NYSE:LLY
883B USD 16.9 42.8
US
Johnson & Johnson
NYSE:JNJ
553.5B USD 8.8 26.3
CH
Roche Holding AG
SIX:ROG
248.4B CHF 6.3 20.1
UK
AstraZeneca PLC
LSE:AZN
216.3B GBP 6.4 28
US
Merck & Co Inc
NYSE:MRK
270.2B USD 5.7 14.8
CH
Novartis AG
SIX:NOVN
216.3B CHF 7.4 20.7
IE
Endo International PLC
LSE:0Y5F
244.4B USD 160.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 5.2 11.8
US
Pfizer Inc
NYSE:PFE
149.3B USD 4.2 19.5
US
Bristol-Myers Squibb Co
NYSE:BMY
122B USD 4.4 17.3

Market Distribution

Lower than 73% of companies in China
Percentile
27th
Based on 6 967 companies
27th percentile
7.4
Low
0 — 8
Typical Range
8 — 23.3
High
23.3 —
Distribution Statistics
China
Min 0
30th Percentile 8
Median 13.6
70th Percentile 23.3
Max 17 898 541.1

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Glance View

Market Cap
30.8B CNY
Industry
Pharmaceuticals

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd, rooted in the rich tapestry of traditional Chinese medicine, has carved out a substantial presence in the pharmaceutical industry. Established in a region known for its deep cultural heritage in holistic healing, the company seamlessly weaves ancient practices with modern scientific advancements. At the core of its operations, Da Ren Tang specializes in the research, development, production, and distribution of traditional Chinese medicine and pharmaceuticals. Beyond just leveraging ancient recipes, the company invests significantly in cutting-edge research to validate and enhance the efficacy of its formulations, gaining trust not only domestically but also in international markets. This blending of tradition and innovation enables Da Ren Tang to capture a diverse customer base, ranging from individuals seeking natural remedies to medical institutions incorporating holistic approaches into patient care. The economic engine of Da Ren Tang powers through a multi-faceted monetization strategy. It manufactures a broad portfolio of pharmaceutical products, including patented Chinese medicines and active pharmaceutical ingredients (APIs), which are distributed through a well-established network of pharmacies and healthcare providers. Additionally, the company has embraced the digital era by exploring e-commerce platforms, thereby expanding its reach and accessibility to tech-savvy consumers globally. By maintaining stringent quality controls and adopting sustainable practices in its production processes, Da Ren Tang not only enhances its reputation but also adheres to evolving regulatory standards worldwide. Such strategic positioning allows the company to capitalize on the growing global interest in traditional medicines, contributing significantly to its revenue streams and reinforcing its status as a prominent player in the pharmaceutical landscape.

Intrinsic Value
37.33 CNY
Overvaluation 7%
Intrinsic Value
Price ¥39.96
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett